Dr. Elliot Tapper Breaks Down What Clinicians Must Know About MASLD
A leading hepatologist from University of Michigan shares essential first steps for managing metabolic dysfunction-associated steatotic liver disease.
Summary
Dr. Elliot Tapper, Academic Chief of Hepatology at University of Michigan Health, joins the Beyond Journal Club podcast from Core IM and NEJM Group to address the first things clinicians should know when managing metabolic dysfunction-associated steatotic liver disease (MASLD). The source material is a brief promotional description; specific clinical content, data, and recommendations are not detailed in the promo and require listening to the full episode at coreimpodcast.com.
Detailed Summary
This entry summarizes a promotional announcement for a Beyond Journal Club podcast episode (from Core IM and NEJM Group) featuring Dr. Elliot Tapper, Academic Chief of Hepatology at University of Michigan Health. The episode addresses the question: what are the first things to know when managing metabolic dysfunction-associated steatotic liver disease (MASLD)?
The promotional material itself does not provide clinical data, statistics, diagnostic algorithms, or therapeutic recommendations. It identifies the topic (initial management of MASLD), the guest (Dr. Tapper), and directs listeners to the full episode at coreimpodcast.com.
MASLD is the current preferred nomenclature for what was previously called non-alcoholic fatty liver disease (NAFLD), reflecting a broader recognition of metabolic drivers of the condition. However, any specific claims about prevalence, diagnostic workup (such as non-invasive fibrosis testing or biopsy criteria), risk stratification frameworks, cardiometabolic co-management, lifestyle interventions, or pharmacologic options — including GLP-1 receptor agonists — are not contained in this promotional source and would require listening to the full podcast episode to verify.
Readers interested in Dr. Tapper's actual clinical guidance should access the full episode directly. This summary intentionally avoids extrapolating content beyond what the promotional blurb provides.
Key Findings
- The podcast episode features Dr. Elliot Tapper, Academic Chief of Hepatology at University of Michigan Health, addressing initial management of MASLD.
- The episode is part of the Beyond Journal Club series, a collaboration between Core IM and NEJM Group.
- The promotional material does not itself contain clinical data, statistics, or specific recommendations — those are in the full audio episode.
- MASLD is the updated terminology for what was previously called NAFLD, though the promo does not elaborate on this shift.
- Full episode access is available at coreimpodcast.com.
Methodology
This is a promotional announcement for an expert clinical discussion podcast, not a primary research study. The source material is a brief social/promotional blurb and does not include clinical content itself; the actual clinical discussion resides in the full episode audio.
Study Limitations
This summary is based solely on a brief promotional blurb for the podcast episode. The blurb contains no clinical data, statistics, diagnostic details, or therapeutic recommendations. Any specific clinical content requires listening to the full episode at coreimpodcast.com.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: